hematopoiet
transplant
use
treat
mani
disord
includ
neoplast
hematolog
immunolog
metabol
diseas
current
hematopoiet
transplant
perform
treatment
hematolog
malign
hematopoiet
cell
transplant
collect
variou
sourc
includ
bone
marrow
peripher
blood
umbil
cord
blood
autolog
transplant
util
patient
cell
wherea
allogen
transplant
util
cell
obtain
differ
individu
syngen
transplant
genet
ident
twin
condit
therapi
given
prior
hematopoiet
transplant
myeloabl
nonmyeloabl
ie
reduc
intens
produc
signific
neutropenia
absolut
neutrophil
count
anc
cellsmm
common
predispos
factor
develop
bacteri
fungal
infect
preengraft
phase
neutropenia
prolong
recipi
myeloabl
allogen
transplant
recipi
nonmyeloabl
autolog
transplant
thu
frequenc
sever
infect
allogen
transplant
recipi
greater
transplant
subgroup
patient
hematolog
malign
may
normal
even
elev
anc
may
increas
risk
infect
due
defect
neutrophil
function
qualit
neutropenia
defect
includ
signific
reduct
phagocytosi
decreas
bactericid
fungicid
activ
decreas
product
superoxid
anion
defect
granulocyt
locomot
myeloabl
condit
regimen
also
inflict
substanti
damag
mucos
barrier
caus
mucos
mouth
gastrointestin
tract
result
increas
risk
infect
aris
site
earli
recognit
aggress
manag
infect
critic
overal
surviv
hematopoiet
transplant
recipi
delay
administr
appropri
antiinfect
therapi
associ
poorer
outcom
unfortun
sign
symptom
commonli
associ
infect
may
blunt
highli
immunosuppress
patient
often
manifest
infect
episod
neutropenia
fever
condit
commonli
refer
febril
neutropenia
wide
accept
definit
febril
neutropenia
oral
temperatur
two
consecut
read
h
period
absolut
neutrophil
count
estim
approxim
allogen
transplant
recipi
smaller
substanti
proport
allogen
transplant
recipi
develop
febril
neutropenia
import
keep
mind
neutropen
patient
especi
receiv
corticosteroid
may
mount
adequ
inflammatori
respons
may
afebril
even
hypotherm
develop
harbor
signific
infect
high
index
suspicion
close
monitor
period
increas
risk
essenti
patient
administr
prompt
broadspectrum
empir
antimicrobi
therapi
becom
standard
care
febril
neutropen
patient
includ
transplant
recipi
gener
principl
therapi
adult
pediatr
patient
publish
guidelin
issu
variou
learn
societi
specif
treatment
regimen
individu
patient
gener
take
consider
local
epidemiolog
trend
local
susceptibilityresist
pattern
sinc
geograph
institut
differ
occur
period
surveil
studi
monitor
chang
epidemiolog
infect
suscept
resist
pattern
import
especi
institut
perform
larg
number
hematopoiet
transplant
although
fever
frequent
occasion
manifest
infect
neutropen
patient
substanti
number
patient
remain
febril
without
specif
infect
document
specif
caus
pathogen
often
bacteri
fungal
identifi
febril
neutropen
episod
refer
episod
microbiolog
document
infect
addit
patient
identifi
site
infect
eg
pneumonia
cellul
enterocol
neg
cultur
fig
may
due
variou
reason
use
antimicrobi
prophylaxi
may
render
cultur
neg
substanti
delay
time
posit
blunt
inflammatori
respons
result
pauciti
specimen
eg
sputum
cultur
episod
refer
clinic
document
infect
approxim
febril
neutropen
patient
neither
clinic
evid
infect
posit
microbiolog
document
one
refer
episod
unexplain
fever
major
episod
probabl
caus
undetect
infect
respond
empir
antimicrobi
therapi
small
proport
patient
fever
neutropenia
noninfecti
caus
fever
drug
fever
tumor
fever
surpris
sinc
fever
induc
cytokin
releas
limit
infect
febril
neutropen
patient
undergo
thorough
evalu
detect
infect
possibl
noninfecti
etiolog
entertain
microbiolog
document
infect
monomicrobi
ie
caus
one
organ
gramposit
bacteria
predomin
howev
polymicrobi
infect
document
increas
frequenc
mani
transplant
center
may
account
bacteri
infect
recent
data
show
bacteremia
neutropen
patient
polymicrobi
infect
involv
deep
tissu
site
pneumonia
enterocol
perirect
infect
often
polymicrobi
polymicrobi
infect
caus
multipl
bacteri
speci
although
bacteri
fungal
bacteri
viral
fungal
viral
infect
may
present
time
infect
gener
associ
greater
morbid
mortal
monomicrobi
infect
common
site
infect
document
neutropen
hematopoiet
transplant
recipi
list
tabl
infect
respiratori
tract
occur
often
follow
bloodstream
infect
includ
central
lineassoci
bloodstream
infect
clabsi
urinari
tract
infect
skin
skin
structur
infect
sssi
infect
origin
oropharynx
gastrointestin
tract
biliari
tract
less
frequent
clinic
import
site
includ
central
nervou
system
musculoskelet
system
end
organ
spleen
liver
frequenc
bloodstream
infect
bsi
vari
center
center
also
type
transplant
gener
frequent
allogen
transplant
recipi
recent
data
indic
incid
least
one
episod
bsi
around
attribut
mortal
approxim
patient
profound
neutropenia
last
day
develop
lung
infiltr
often
respond
broadspectrum
antimicrobi
therapi
establish
specif
diagnosi
patient
remain
signific
challeng
data
regard
site
infect
robust
describ
bsi
unexplain
fever
clinic
document
infect
predominantli
respiratori
ssi
microbiolog
document
infect
predominantli
bacteri
fungal
non
infecti
caus
fever
predominantli
drug
tumor
fever
microbiolog
document
infect
aris
patient
endogen
microflora
small
proport
acquir
exogen
sourc
andor
environment
exposur
therefor
often
possibl
anticip
potenti
etiolog
infect
provid
appropri
empir
coverag
base
site
infect
origin
exampl
infect
cutan
origin
caus
staphylococcu
speci
organ
colon
skin
bacillu
spp
corynebacterium
spp
candida
spp
patient
sever
oral
mucos
andor
poor
periodont
statu
like
infect
caus
viridan
group
streptococci
vg
stomatococcu
mucilaginosu
patient
signific
lower
intestin
mucos
enterococc
gramneg
bacillari
infect
occur
often
bacteri
infect
gener
occur
initi
stage
neutropen
episod
fungal
infect
aris
frequent
patient
prolong
day
neutropenia
widespread
use
longterm
central
venou
cathet
transplant
recipi
impact
frequenc
spectrum
infect
abil
certain
organ
notabl
coagulaseneg
staphylococci
con
staphylococcu
aureu
candida
spp
produc
get
embed
biofilm
poor
penetr
mani
antimicrobi
agent
biofilm
make
catheterrel
infect
difficult
erad
without
remov
offend
cathet
consequ
mani
transplant
center
perform
routin
weekli
blood
cultur
central
venou
cathet
attempt
detect
colonizationinfect
earli
practic
howev
shown
accur
predict
develop
clabsi
may
lead
unnecessari
intervent
common
organ
isol
clabsi
con
organ
includ
aureu
bacillu
spp
corynebacterium
spp
pseudomona
aeruginosa
enterobacteriacea
enterococcu
spp
acinetobact
spp
stenotrophomona
maltophilia
candida
spp
despit
widespread
use
cathet
infect
rate
seldom
exce
two
episod
per
cathet
day
sever
recent
epidemiolog
survey
conduct
pediatr
adult
hematopoiet
transplant
recipi
document
predomin
gramposit
organ
gramneg
bacilli
reason
predomin
includ
widespread
use
central
venou
cathet
frequent
use
intens
chemotherapeut
regimen
produc
signific
oral
mucos
use
antibacteri
prophylaxi
gener
fluoroquinolon
direct
primarili
enter
gramneg
bacilli
fluoroquinolon
prophylaxi
fact
show
increas
frequenc
gramposit
infect
especi
organ
vg
often
resist
proport
gramposit
infect
report
high
center
mani
report
howev
includ
data
bsi
caus
singl
organ
monomicrobi
bsi
either
exclud
provid
littl
detail
regard
infect
site
polymicrobi
infect
report
provid
overestim
gramposit
infect
sinc
major
bacteremia
particularli
clabsi
inde
caus
gramposit
organ
inhabit
skin
mention
previous
bsi
account
microbiolog
document
infect
infect
site
lung
intestin
tract
urinari
tract
biliari
tract
predomin
gramneg
pathogen
addit
polymicrobi
infect
gramneg
compon
caus
exclus
multipl
gramneg
speci
therefor
site
infect
bsi
monomicrobi
well
polymicrobi
infect
pool
togeth
appar
predomin
gramposit
organ
seem
less
strike
gramneg
organ
isol
almost
frequent
inde
institut
begin
report
resurg
frequenc
gramneg
pathogen
even
patient
bsi
main
reason
appear
discontinu
fluoroquinolon
prophylaxi
institut
sinc
practic
result
emerg
fluoroquinoloneresist
even
multidrugresist
organ
reason
remain
unclear
anaerob
seldom
isol
neutropen
patient
although
customari
provid
anaerob
coverag
especi
infect
aris
involv
intestin
tract
realtim
knowledg
local
epidemio
coagulaseneg
staphylococci
isol
often
common
speci
staphylococcu
epidermidi
homini
haemolyticu
organ
low
virul
seldom
caus
lifethreaten
infect
even
sever
neutropen
patient
clabsi
common
infect
caus
con
often
treat
antimicrobi
agent
alon
although
cathet
remov
may
requir
infect
recur
one
except
lugdunensi
close
resembl
aureu
virul
mani
expert
recommend
organ
consid
harmless
commens
infect
caus
manag
like
caus
aureu
gramposit
organ
colon
human
skin
caus
infect
neutropen
patient
includ
bacillu
spp
corynebacterium
spp
micrococcu
spp
like
con
organ
caus
clabsi
often
although
seriou
infect
endophthalm
endocard
septic
arthriti
pneumonia
develop
occasion
mention
aureu
virul
staphylococci
associ
substanti
morbid
mortal
patient
aureu
bacteremia
evalu
infect
endocard
deepseat
abscess
unlik
con
cathet
remov
almost
alway
necessari
aureu
clabsi
concern
increas
rate
methicillin
resist
among
aureu
mrsa
isol
worldwid
although
mrsa
rate
low
still
report
occasion
mani
institut
report
mrsa
rate
rang
make
common
methicillinsuscept
isol
mrsa
isol
develop
toler
mbc
time
mic
reduc
suscept
vancomycin
refer
mic
creep
therebi
reduc
therapeut
impact
agent
recent
consid
agent
choic
treatment
gramposit
infect
neutropen
patient
altern
agent
recommend
infect
caus
organ
alphahemolyt
streptococci
vg
major
compon
human
oral
microflora
patient
particularli
prone
vg
infect
recipi
highintens
chemotherapi
agent
cytosin
arabinosid
induc
sever
mucos
damag
facilit
transloc
organ
bloodstream
predispos
factor
includ
use
fluoroquinolon
prophylaxi
use
antacid
histamin
antagonist
although
recommend
author
vancomycinbas
prophylaxi
peritranspl
period
use
order
reduc
frequenc
vg
bacteremia
practic
requir
close
monitor
patient
develop
resist
organ
vre
andor
staphylococc
isol
reduc
suscept
resist
vancomycin
consid
institut
frequenc
infect
caus
vg
high
also
concern
possibl
practic
might
lead
develop
reduc
suscept
agent
daptomycin
dalbavancin
investig
believ
mucos
gener
occur
nadir
neutropenia
primari
predispos
factor
develop
infect
set
coin
phrase
febril
mucos
addit
periodont
inflamm
includ
gingiv
periodont
increas
possibl
vg
bacteremia
common
manifest
vg
infect
bacteremia
approxim
patient
may
develop
dissemin
infect
socal
streptococc
toxic
shock
syndrom
mortal
rate
rang
despit
appropri
therapi
streptococcu
miti
sangui
salivariu
speci
isol
often
patient
vg
bacteremia
increas
concern
report
vg
isol
nonsuscept
overtli
resist
penicillin
isol
current
suscept
vancomycin
although
occasion
toler
agent
describ
also
suscept
newergener
quinolon
moxifloxacin
agent
linezolid
daptomycin
telavancin
dalbavancin
although
clinic
experi
agent
limit
use
antibiot
combin
may
warrant
especi
organ
high
mic
toler
vancomycin
enterococci
resid
mainli
lower
intestin
tract
seldom
primari
pathogen
isol
often
follow
prolong
therapi
broadspectrum
agent
carbapenem
common
manifest
includ
bsi
urinari
tract
infect
enterococci
also
often
isol
polymicrobi
infect
neutropen
enterocol
perirect
infect
increas
prolong
use
vancomycin
neutropen
patient
part
respons
emerg
vancomycinresist
enterococci
vre
global
current
enterococc
isol
unit
state
vre
fecal
colon
vre
hematopoiet
transplant
recipi
uncommon
approxim
colon
patient
develop
bsi
seriou
infect
consequ
expert
recommend
preemptiv
use
agent
activ
vre
patient
fecal
colon
develop
febril
neutropenia
fecal
decolon
attempt
attempt
unsuccess
therefor
antimicrobi
stewardship
infect
control
measur
limit
emerg
spread
vre
extrem
import
gastrointestin
tract
serv
import
sourc
infect
neutropen
patient
predomin
pathogen
enter
gramneg
bacilli
use
antimicrobi
prophylaxi
highrisk
neutropen
patient
includ
hematopoiet
transplant
recipi
led
declin
frequenc
extent
morbid
mortal
associ
document
gramneg
infect
practic
also
led
emerg
resist
among
escherichia
coli
gramneg
speci
therefor
mani
institut
reevalu
practic
institut
even
discontinu
fluoroquinolon
prophylaxi
neutropen
patient
mani
institut
conduct
surveil
studi
highrisk
patient
look
fecal
colon
vre
pseudomona
aeruginosa
resist
organ
extendedspectrum
betalactamas
esbl
produc
carbapenemresist
enterobacteriacea
cre
sinc
posit
surveil
cultur
often
predict
develop
infect
subsequ
episod
neutropenia
inform
use
pick
appropri
empir
regimen
colon
patient
develop
febril
neutropenia
well
antimicrobi
stewardship
effort
surveil
cultur
neg
esblproduc
organ
report
increas
frequenc
carbapenemaseproduc
gramneg
bacteria
klebsiella
pneumonia
carbapenemas
kpc
new
delhi
metallobetalactamas
nonmetallobetalactamas
produc
emerg
past
year
spread
across
globe
gramneg
infect
usual
associ
greater
morbid
mortal
gramposit
infect
mani
epidemiolog
studi
shown
e
coli
klebsiella
speci
k
pneumonia
k
oxytoca
p
aeruginosa
remain
three
primari
gramneg
pathogen
neutropen
patient
caus
infect
enterobacteriacea
citrobact
spp
enterobact
spp
proteu
spp
serratia
spp
less
common
although
institut
differ
exist
nationwid
outbreak
serratia
marcescen
bacteremia
due
contamin
prefil
heparin
salin
syring
report
despit
overal
declin
frequenc
gramneg
infect
proport
infect
caus
nonfer
gramneg
bacilli
nfgnb
p
aeruginosa
nonaeruginosa
pseudomonad
stenotrophomona
maltophilia
acinetobact
speci
increas
collect
nfgnb
caus
gramneg
infect
proport
steadili
increas
past
two
decad
p
aeruginosa
import
frequent
isol
nfgnb
caus
gramneg
infect
bacteremia
pneumonia
two
common
manifest
although
infect
variou
site
uncommon
also
common
gramneg
organ
isol
polymicrobi
infect
organ
develop
resist
antimicrobi
agent
use
multipl
mechan
often
acquir
resist
sever
class
agent
multidrug
resist
mdr
difficult
treat
erad
combin
therapi
often
necessari
prolong
use
fluoroquinolon
carbapenem
identifi
risk
factor
develop
resist
consequ
mani
antimicrobi
stewardship
effort
focu
curtail
minim
use
agent
colonizationinfect
maltophilia
also
report
often
especi
patient
hematolog
malign
hematopoiet
transplant
recipi
shift
trimethoprimsulfamethoxazol
potent
activ
maltophilia
fluoroquinolon
prefer
agent
antimicrobi
prophylaxi
neutropen
patient
may
account
increas
organ
almost
alway
multidrug
resist
case
p
aeruginosa
combin
therapi
trimethoprimsulfamethoxazol
minocyclin
tigecyclin
frequent
necessari
infrequ
import
nfgnb
includ
acinetobact
spp
achromobact
alcaligen
spp
nonaeruginosa
pseudomona
speci
p
putida
p
fluorescen
mani
outbreak
caus
organ
trace
contamin
dialysi
fluid
deioniz
water
mechan
ventil
chlorhexidin
solut
mani
organ
also
multidrug
resist
anaerob
infect
seldom
document
febril
neutropen
patient
overal
rang
posit
blood
cultur
common
site
infect
intestin
tract
neutropen
enterocol
perirect
infect
abdominalpelv
abscess
complic
skin
skin
structur
infect
biliari
tract
infect
respiratori
infect
customari
provid
anaerob
coverag
treat
infect
even
anaerob
isol
presenc
signific
oral
intestin
mucos
increas
risk
anaerob
infect
purul
hallmark
anaerob
infect
immunocompet
patient
often
absent
patient
neutropenia
organ
isol
often
includ
peptostreptococcu
spp
fusobacterium
nucleatum
bacteroid
spp
prevotella
spp
clostridium
spp
due
frequent
prolong
use
broadspectrum
antimicrobi
agent
clostridium
difficileassoci
diarrhea
infrequ
patient
neutropenia
approxim
hematopoiet
transplant
recipi
develop
c
difficil
infect
mainli
month
posttransplant
colon
toxigen
strain
c
difficil
shown
predict
develop
c
difficileassoci
diarrhea
hematopoiet
transplant
recipi
respons
treatment
may
lower
relaps
recurr
infect
may
higher
set
spectrum
bacteri
infect
neutropen
patient
continu
chang
signific
geograph
institut
differ
commonplac
institut
wherein
fluoroquinolon
prophylaxi
still
use
gramposit
pathogen
predomin
wherea
institut
suspend
discontinu
use
fluoroquinolon
prophylaxi
gramneg
pathogen
common
resist
pattern
also
vari
region
region
inde
sometim
within
region
institut
resist
organ
uncommon
scandinavian
countri
vre
appear
common
unit
state
europ
frequenc
esblproduc
carbapenemaseproduc
mdr
gramneg
organ
appear
increas
worldwid
consequ
gener
realtim
local
epidemiolog
suscept
resist
data
import
bacteri
infect
predomin
initi
day
neutropenia
prolong
neutropenia
fungal
infect
begin
develop
infect
caus
candida
spp
aspergillu
spp
document
often
although
mani
opportunist
fungi
pathogen
set
tabl
invas
candidiasi
common
fungal
infect
neutropen
patient
prior
develop
agent
fluconazol
c
albican
predomin
speci
routin
usag
antifung
prophylaxi
highrisk
patient
includ
hematopoiet
transplant
recipi
frequenc
invas
candidiasi
substanti
reduc
manifest
like
esophag
chronic
system
hepatosplen
candidiasi
becom
almost
histor
interest
current
candidemia
often
catheterrel
common
manifest
invas
candidiasi
also
shift
epidemiolog
candidiasi
part
relat
usag
agent
fluconazol
emerg
candida
speci
c
albican
c
glabrata
c
tropicali
c
parapsilosi
c
krusei
c
auri
frequent
pathogen
set
region
differ
document
preponder
differ
speci
differ
institut
differ
may
due
diverg
use
antifung
prophylaxi
andor
geograph
divers
bacteri
infect
local
epidemiolog
susceptibilityresist
data
use
guid
empir
target
antifung
therapi
yeast
occasion
encount
set
includ
trichosporon
beigelii
hansenula
anomala
geotrichum
capitatum
malassezia
furfur
streptomyc
cerevisia
invas
mold
infect
common
lifethreaten
infect
patient
neutropenia
last
longer
week
vast
major
infect
caus
aspergillu
speci
fumigatu
predomin
speci
speci
aspergillu
emerg
signific
pathogen
well
includ
flavu
terreu
niger
oryza
tabl
common
site
involv
lung
result
invas
pulmonari
aspergillosi
ipa
frequent
site
involv
includ
paranas
sinus
central
nervou
system
fungemia
rare
document
although
still
rel
uncommon
mucormycosi
emerg
increasingli
import
infect
neutropen
patient
last
year
common
organ
caus
infect
mucor
spp
rhizopu
spp
rhizomucor
spp
cunninghamella
spp
absidia
spp
increas
frequenc
mucormycosi
part
attribut
use
voriconazol
due
lack
activ
organ
like
aspergillosi
common
site
infect
includ
paranas
sinus
rhinoorbit
area
lung
central
nervou
system
uncommon
import
mold
caus
infect
set
includ
fusarium
spp
scedosporium
spp
unlik
mold
fungemia
common
manifest
fusariosi
may
occur
patient
necrot
cutan
lesion
also
rel
common
incid
scedosporium
infect
appear
increas
recent
year
increas
may
also
relat
fact
organ
resist
mani
commonli
use
antifung
agent
viral
infect
especi
caus
human
herp
virus
common
highrisk
patient
neutropenia
includ
hematopoiet
cell
transplant
recipi
effect
prevent
antivir
prophylaxi
andor
preemptiv
therapi
herp
simplex
viru
hsv
hsv
infect
adult
due
reactiv
latent
infect
seroposit
patient
likelihood
viral
reactiv
depend
intens
chemotherapeuticcondit
regimen
reactiv
occur
twothird
patient
undergo
induct
chemotherapi
acut
myelogen
leukemia
recipi
hematopoiet
transplant
absenc
antivir
prophylaxi
ulcer
oral
esophag
mucosa
ulcer
vesicl
lip
genitalia
skin
perian
area
common
manifest
hsv
caus
numer
syndrom
includ
enceph
mening
myeliti
esophag
hepat
ocular
diseas
pneumonia
erythema
multiform
reactiv
less
commonli
primari
acquisit
human
herp
virus
cytomegaloviru
epsteinbarr
viru
human
herp
viru
also
occur
albeit
seen
mostli
late
transplant
period
infect
caus
respiratori
virus
may
necessarili
occur
frequent
neutropen
patient
manifest
tend
sever
set
may
even
impact
decis
proceed
hematopoiet
cell
transplant
sever
guidelin
recommend
delay
transplant
patient
pretranspl
upper
respiratori
tract
infect
pathogen
includ
influenza
virus
influenza
b
respiratori
syncyti
viru
rsv
parainfluenza
virus
adenoviru
metapneumoviru
risk
infect
organ
tend
coincid
respiratori
viru
outbreak
gener
popul
sever
infect
specif
rate
progress
upper
respiratori
tract
diseas
lower
respiratori
tract
diseas
pneumonia
depend
level
durat
type
immunosuppress
includ
influenza
b
parainfluenza
virus
respiratori
syncyti
viru
rsv
human
metapneumoviru
corona
virus
rhinovirus
bocaviru
infect
may
necessarili
common
neutropen
patient
tend
sever
previous
mention
approxim
microbiolog
document
infect
polymicrobi
past
polymicrobi
infect
ignor
underappreci
underreport
late
greater
attent
paid
infect
gener
associ
greater
morbid
mortal
monomicrobi
infect
may
polymicrobi
infect
frequent
involv
deep
tissu
pneumonia
empyema
neutropen
enterocol
perirect
infect
penetr
antimicrobi
agent
might
subtherapeut
larg
area
perfus
necrot
tissu
may
present
recent
studi
also
show
bacterem
infect
includ
clabsi
polymicrobi
gramposit
organ
predominantli
staphylococci
enterococci
isol
polymicrobi
infect
wherea
gramneg
organ
isol
polymicrobi
infect
p
aeruginosa
e
coli
isol
often
approxim
onethird
caus
multipl
gramneg
speci
eg
e
coli
p
aeruginosa
occasion
bacteri
fungal
bacteri
viral
fungal
viral
multipl
fungal
infect
may
coexist
import
rememb
neutropenia
often
superimpos
immunolog
defect
impair
cellular
humor
immun
result
underli
malign
andor
treatment
prior
transplant
deficit
present
addit
neutropenia
spectrum
infect
widen
consider
deficit
associ
uniqu
set
pathogen
principl
manag
episod
febril
neutropenia
develop
refin
sever
decad
mani
societi
includ
infecti
diseas
societi
america
idsa
nation
comprehens
cancer
network
nccn
american
societi
clinic
oncolog
asco
european
societi
medic
oncolog
esmo
publish
evidencebas
guidelin
provid
current
inform
regard
manag
includ
prevent
episod
febril
neutropen
patient
undergo
quick
thorough
initi
evalu
receiv
prompt
broadspectrum
empir
antibiot
therapi
base
current
local
epidemiolog
susceptibilityresist
pattern
sever
option
avail
initi
empir
therapi
includ
monotherapi
broadspectrum
antipseudomon
agent
variou
combin
regimen
depend
patient
risk
group
therapi
may
administ
hospit
outpati
set
may
parenter
oral
close
monitor
respons
progress
infect
develop
complic
drugrel
advers
effect
develop
superinfect
critic
modif
initi
regimen
may
requir
patient
depend
risk
group
natur
site
infect
develop
superinfect
includ
suspect
document
fungal
infect
remov
infect
cathet
medic
hardwar
may
necessari
surgic
intervent
may
indic
specif
set
eg
perirect
infectionabscess
overal
durat
therapi
depend
sever
factor
patient
risk
group
natur
site
infect
resolut
persist
neutropenia
principl
discuss
detail
histori
taken
includ
natur
intens
chemotherapi
prior
antibiot
usag
prophylact
therapeut
use
corticosteroid
immunosuppress
agent
recent
surgic
procedur
includ
placement
medic
hardwar
allergi
recent
travel
potenti
exposur
sick
contact
histori
past
infect
andor
colon
resist
organ
also
impact
select
appropri
empir
antimicrobi
regimen
thorough
physic
examin
mandatori
often
reveal
import
site
infect
includ
cutan
lesion
ecthyma
gangrenosum
cellul
perirect
infectionabscess
examin
cathet
insert
site
extern
auditori
meatu
nare
nasal
septum
oropharynx
may
also
often
reveal
foci
infect
addit
import
rememb
neutropen
patient
especi
receiv
corticosteroid
may
afebril
other
may
feel
unwel
may
even
hypotherm
patient
may
harbor
seriou
infect
gramneg
septicemia
laboratori
evalu
includ
complet
blood
count
cbc
differenti
leucocyt
count
platelet
count
measur
serum
creatinin
blood
urea
nitrogen
bun
assess
renal
function
measur
serum
electrolyt
total
bilirubin
hepat
transaminas
enzym
least
two
set
blood
cultur
obtain
one
peripher
vein
central
venou
cathet
present
lumen
multilumen
cathet
cultur
separ
cultur
specimen
site
urin
wound
sputum
avail
obtain
indic
chest
radiograph
recommend
routin
obtain
patient
respiratori
symptom
sign
initi
evalu
febril
neutropen
patient
also
includ
risk
assess
guid
choic
empir
antibiot
regimen
combin
vs
monotherapi
rout
administr
parenter
vs
oral
set
therapi
administ
hospit
vs
outpati
durat
therapi
commonli
use
risk
assess
system
adult
mascc
risk
index
highrisk
patient
mascc
risk
score
admit
hospit
empir
therapi
close
monitor
lowrisk
patient
mascc
risk
score
may
candid
outpati
oral
parenter
therapi
separ
risk
assess
tool
avail
pediatr
febril
neutropen
patient
algorithm
manag
febril
neutropen
patient
provid
fig
initi
evalu
risk
assess
complet
empir
antibiot
therapi
administ
without
undu
delay
lowrisk
patient
treat
oral
parenter
regimen
tabl
administ
short
period
hospit
follow
outpati
therapi
treatment
entir
episod
outpati
set
oral
regimen
fluoroquinolonebas
combin
although
fluoroquinolon
monotherapi
also
shown
safe
effect
import
point
hematopoiet
cell
transplant
recipi
even
receiv
nonmyeloabl
andor
autolog
transplant
seldom
fall
lowrisk
categori
hematopoiet
transplant
recipi
febril
neutropenia
either
alreadi
hospit
requir
hospit
administr
parenter
antibiot
therapi
monotherapi
antipseudomon
betalactam
agent
cefepim
carbapenem
meropenem
imipenemcilastatin
ertapenem
activ
p
aeruginosa
piperacillintazobactam
recommend
tabl
agent
aminoglycosid
fluoroquinolon
tigecyclin
polymyxincolistin
metronidazol
may
need
antimicrobi
resist
suspect
document
specif
pathogen
esblproduc
carbapenemaseproduc
gramneg
bacillu
anaerob
isol
initi
use
agent
vancomycin
daptomycin
linezolid
discourag
except
prior
colon
infect
resist
gramposit
organ
mrsa
vre
document
catheterrel
infect
strongli
suspect
empir
use
vancomycin
shown
reduc
overal
mortal
patient
gramposit
infect
possibl
except
infect
caus
vg
addit
one
recent
studi
demonstr
empir
use
linezolid
febril
neu
tabl
tropen
patient
colon
vre
impact
mortal
well
concern
also
rais
develop
linezolid
resist
alreadi
report
increas
usag
agent
empir
antifung
coverag
institut
patient
remain
febril
day
durat
therapi
continu
vigor
debat
patient
episod
unexplain
fever
therapi
gener
continu
marrow
recoveri
anc
cell
mm
consecut
day
expert
recommend
discontinu
therapi
patient
defervesc
even
though
marrow
recoveri
defin
yet
occur
recommend
place
patient
initi
prophylact
regimen
neutropenia
resolv
patient
microbiolog
clinic
document
infect
durat
therapi
usual
depend
site
infect
cellul
uti
requir
shorter
durat
bacteremia
pneumonia
organ
isol
patient
clabsi
caus
aureu
p
aeruginosa
candida
spp
fungi
mycobacteria
cathet
remov
addit
appropri
antimicrobi
therapi
recommend
therapi
gener
continu
marrow
recoveri
longer
clinic
indic
ultim
decis
stop
therapi
often
need
individu
may
depend
numer
factor
patient
risk
group
presenc
document
infect
andor
persist
neutropenia
hand
hygien
cutan
antisepsi
maximum
steril
barrier
precaut
recommend
procedur
cvc
insert
bone
marrow
biopsi
strict
adher
infect
control
practic
polici
essenti
minim
spread
infect
control
outbreak
especi
caus
resist
organ
hospit
healthcar
set
antimicrobi
stewardship
essenti
especi
sinc
frequent
use
antimicrobi
therapi
highrisk
patient
creat
select
pressur
lead
develop
resist
variou
strategi
antimicrobi
stewardship
list
tabl
includ
multidisciplinari
antibiot
stewardship
team
mast
institut
pathwaysguidelin
formulari
restrict
preapprov
requir
certain
agent
deescal
streamlin
therapi
appropri
feasibl
antimicrobi
stewardship
program
success
institut
sever
institut
although
current
primari
focu
program
stewardship
antibacteri
agent
anticip
program
soon
expand
includ
antifung
antivir
agent
well
